EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Humoral epitope dominance and immune imprinting by SARS ‐ CoV ‐1 and SARS ‐ CoV ‐2 vaccines

Deborah L Burnett iD, Ania Moxon, Anupriya Aggarwal, Katherine Jl Jackson, Catherine Cotter, Anouschka Akerman, Amanda Russell, Rachel Kalman, David Langley, Jake Y Henry, Daniel Christ, Rowena A Bull und 6 weitere

Immunology & Cell Biology · 2026

DOI: 10.1111/imcb.70072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology & Cell Biology, 2026. Verfasst von Deborah L Burnett und 17 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: SARS-CoV-2, Spike Glycoprotein, Coronavirus, COVID-19 Vaccines, COVID-19. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, NSW Ministry of Health, Ramaciotti Foundations.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long‐lasting protective immunity against sarbecoviruses is hampered by the dominance of elicited antibodies to variable parts of the Spike protein, allowing ongoing viral escape and evolution. We investigated Modified Vaccinia Ankara (MVA) vaccine candidates expressing the SARS‐CoV‐1 or SARS‐CoV‐2 Spike for their ability to induce antibodies targeting different epitopes on the SARS‐CoV‐2 Receptor Binding Domain (RBD), including those with wide variant conservation. We also explored the capacity of these different Spike proteins to induce broad cross‐reactive or cross‐neutralizing B cells against multiple variants. This revealed that the SARS‐CoV‐1 Spike induced distinct patterns of epitope dominance compared to the traditional SARS‐CoV‐2 Spike antigens. Following immune imprinting by previous exposure to ancestral SARS‐CoV‐2 Spike, the epitope dominance patterns induced by SARS‐CoV‐1 and SARS‐CoV‐2 vaccines still differed, with most of the germinal center response consisting of de novo recruited B cells. In addition to the de novo response, B cells with germline cross‐reactivity to both antigens further increased their binding toward the most recently immunized antigen. Interestingly, we found that, while SARS‐CoV‐2 vaccinated animals were extremely capable of mounting an antigen‐specific germinal center and plasmablast response to a booster immunization with SARS‐CoV‐1, SARS‐CoV‐2 boosters were less capable of inducing SARS‐CoV‐2 specific B cells following prior SARS‐CoV‐1 vaccination. These findings have broad implications for the implementation of vaccine strategies against emerging coronavirus variants and potential future coronavirus spillover events. The implications stemming from a fundamental directionality of immune imprinting and epitope dominance may have wider implications for noncoronavirus antigens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Spike Glycoprotein, CoronavirusCOVID-19 VaccinesCOVID-19Severe acute respiratory syndrome-related coronavirusImmunity, HumoralEpitopes, B-LymphocyteImmunodominant EpitopesAnimalsAntibodies, ViralHumansB-LymphocytesCross ReactionsAntibodies, NeutralizingMiceFemale

Stichwörter der Autor:innen

Epitope dominanceSARS‐CoV‐1SARS‐CoV‐2humoral immunitymodified vaccinia ankaravaccines

Substanzen

Spike Glycoprotein, CoronavirusCOVID-19 VaccinesAntibodies, Viralspike protein, SARS-CoV-2Antibodies, NeutralizingEpitopes, B-LymphocyteImmunodominant Epitopes

Autor:innen und Institutionen

  • School of Biomedical Sciences, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.
  • Garvan Institute of Medical Research, Sydney, NSW, Australia.
  • Kirby Institute, UNSW, Sydney, NSW, Australia.
  • Cellular Genomics Futures Institute, UNSW Sydney, Sydney, NSW, Australia.
  • Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
  • Institute for Molecular Bioscience, University of Queensland, St Lucia, QLD, Australia.

ORCID-Profile: Deborah L Burnett

Förderung

  • National Health and Medical Research Council
  • NSW Ministry of Health
  • Ramaciotti Foundations
  • Ms Lysia O'Keefe and a philanthropic gift in memory of Dr and Mrs Wing Kan Fok
  • NIH HHS
  • NSW Health
  • National Institutes of Health

Zitieren

APA

Burnett, D. L., Moxon, A., Aggarwal, A., Jackson, K. J., Cotter, C., Akerman, A., Russell, A., Kalman, R., Langley, D., Henry, J. Y., Christ, D., Bull, R. A., Brink, R., Kelleher, A. D., Jäck, H. M., Turville, S., Moss, B., & Goodnow, C. C. (2026). Humoral epitope dominance and immune imprinting by SARS ‐ CoV ‐1 and SARS ‐ CoV ‐2 vaccines. Immunology & Cell Biology. https://doi.org/10.1111/imcb.70072

Vancouver

Burnett DL, Moxon A, Aggarwal A, Jackson KJ, Cotter C, Akerman A, et al. Humoral epitope dominance and immune imprinting by SARS ‐ CoV ‐1 and SARS ‐ CoV ‐2 vaccines. Immunology & Cell Biology. 2026. doi:10.1111/imcb.70072

BibTeX
@article{Burnett2026,
  author = {Burnett, Deborah L and Moxon, Ania and Aggarwal, Anupriya and Jackson, Katherine Jl and Cotter, Catherine and Akerman, Anouschka and Russell, Amanda and Kalman, Rachel and Langley, David and Henry, Jake Y and Christ, Daniel and Bull, Rowena A and Brink, Robert and Kelleher, Anthony D and Jäck, Hans-Martin and Turville, Stuart and Moss, Bernard and Goodnow, Christopher C},
  title = {Humoral epitope dominance and immune imprinting by SARS ‐ CoV ‐1 and SARS ‐ CoV ‐2 vaccines},
  journal = {Immunology & Cell Biology},
  year = {2026},
  doi = {10.1111/imcb.70072}
}
Kostenlos starten →